Several monoclonal antibodies (MAbs) directed to blood group P1 (Gal alpha 1-4Gal beta 1-4GlcNAc beta-O) and Pk (Gal alpha 1-4Gal beta 1-4Glc beta-O) determinants were produced with high efficiency by using synthetic neoglycoproteins as immunogens. The specificity of IgM and IgG1 MAbs was characterized by binding to defined oligosaccharides and glycoconjugates. Antibodies that bound equally well to P1 and Pk determinants and to Gal alpha 1-4Gal beta 1-O-derivatives were obtained, together with others that showed selective recognition of the entire trisaccharide chain. Selected antibodies were shown to be useful as reagents for detection of the blood group P antigens in glycolipid extracts of erythrocytes and on the surface of erythrocytes of different P phenotypes, demonstrated both by radioimmune assays and hemagglutination. Six IgM MAbs directed to the Pk determinant bound selectively to Burkitt lymphoma cells and 2 of these antibodies (424/3D9 and 424/6A2) could be used as auxiliary reagents in immunofluorescence for diagnosis and classification of B-cell lymphomas and leukemias using flow cytometric analysis. Eight normal individuals and 37 patients with lymphoma or leukemia were studied. Tumor cells of 2/2 patients with "Burkitt-like" lymphoma, 1 patient with centroblastic lymphoma and 2 patients with acute leukemia were strongly stained for the Pk antigen. The staining patterns for differentiation markers classified the tumor cells to a developmental stage closely related to the Burkitt cell type.
The neutral glycosphingolipid (GSL) globotriaosylceramide (Gb3) of the globo-series was recently defined as the CD77 antigen. This B cell-associated antigen is characterized by its specific expression on germinal center B cells. In order to study the potential relation of the CD77 antigen and other GSLs to B cell activation we have performed a comprehensive analysis of the synthesis and expression of neutral GSL in tonsillar B lymphocytes. Monoglycosylceramide (GL1) and lactosylceramide (LacCer) comprised the largest portion of GSL in tonsillar B lymphocytes as detected by HPLC analysis. GSLs of the globo-series Gb3 and globotetraosylceramide (Gb4), were found in smaller amounts. Since other GSLs, like gangliotriaosylceramide (Gg3) and gangliotetraosylceramide (Gg4), could only be detected using highly sensitive antibody reactions, we assume that these GSLs occur in B cells only in minor amounts. When tonsillar B cells were density fractionated on Percoll, the light density cells, which correspond to activated cells, contained and expressed more of both globo-GSLs than cells in the higher density fraction. When the dense fraction of tonsillar B cells was activated in vitro by anti-mu/BCGF, synthesis of GL1, LacCer, Gb3, and Gb4 was biphasic, with maxima at 12 and 84 h. Surface expression of the CD77 antigen on the denser cells was strongly induced by anti-mu/BCGF during the first 24 h of cultivation followed by a rapid decline thereafter, mimicking synthesis. PMA treatment of this cell fraction caused an even stronger expression of the CD77 antigen, which lasted over 48 h of cultivation.(ABSTRACT TRUNCATED AT 250 WORDS)
Rat monodonal antibodies (MAb) directed to mouse Ig heavy and light chain determinants were produced. A rat antimouse light chain MAb (RAMOL.1) which bound to all (24/24) mouse Ig ofthe K light chain type and with varying strength to 4/4 light chain-bearing Ig was evaluated as a general secondary reagent, together with two MAb that bound to the heavy chain of mouse IgG. They were conjugated with biotin or Flit and used in immunohistochemical and immunofluorescence assays to detect mouse monodonal antibodies binding to antigens expressed in rat and human tissues and cells. As compared to commercially available polydonal reagents, RAMOL-1 gave higher staining contrast by showing lower background staining and equal or higher staining of the primary MAb tested. This was a resuit of two main effects. First, crossreactivity with endogenous Ig and tissue type-specific determinants was eliminated.
Monoclonal antibodies (MAbs) were derived from rats immunized against allo- and syngeneic rat colon carcinomas. Screening was performed by immunohistochemistry modified for MAbs of the same species as the tissue used for frozen sections. From 2 fusions, several MAbs were found that bound to syngeneic tumor tissue but showed little or no staining of normal adult tissues. Another group of MAbs demonstrated an intracellular staining of tumor cells and staining of mucus and goblet cells in the distal 2/3 of the normal colon. A third group of MAbs showed staining of both tumor and normal colon tissue. Staining patterns were reproduced with 6 MAbs selected from the first 2 groups after purification and biotinylation. One MAb, 10B12, recognized an antigen expressed in 10/11 colon carcinomas, the lowest parts of colonic crypts, intracellularly in a subpopulation of pancreatic acinar cells and mucus in antrum. It was used for affinity purification of a high-molecular-weight antigen, to which 3 of the other rat MAbs also bound. This antigen was also bound by antibodies to blood group A and isogloboseries carbohydrate determinants. Competition with the labelled 10B12 MAb for binding to the purified antigen was demonstrated in sera of tumor-bearing and immune rats. Thus, this high-molecular-weight glycoprotein expressed both auto-antigenic, tumor-associated and tissue-type-restricted epitopes. The 10B12 MAb homogeneously stained the majority of colorectal carcinomas and the antigenic determinant was expressed on the cell surface of 12/13 tissue-cultured colon-carcinoma clones. Modulation of the cell-surface antigen phenotype by recombinant rat interferon-gamma markedly increased expression of this determinant.
Monoclonal antibodies (MAbs) directed to 2 neutral glycolipids, isoglobotetraosylceramide and a 6-sugar isogloboneolactoseries hybrid glycolipid, previously shown to be enriched in rat colorectal tumor tissue, were produced by immunization with purified glycolipids. Four MAbs were selected which demonstrate 3 different specificity patterns when tested for binding to purified and crude preparations of neutral glycolipids, cultured tumor cells and fibroblasts and frozen tissue sections. MAbs 14.2 and 14.10, but not 14.3, stained most epithelial colorectal carcinomas, rat testis and a subpopulation of cells in the rat gastric mucosa. However, all 3 MAbs showed strong staining and binding to sections and cultured clones of the cytokeratin-negative tumor of colorectal origin, which was originally used for preparation of the glycolipid immunogens. The observed difference between MAbs 14.2/10 and MAb 14.3 could not be explained by differences in binding to the 2 original glycolipids used for screening. However, MAbs 14.2/10 were demonstrated to bind to high-molecular-weight glycoprotein(s) (HMW-gp's) previously shown to carry determinants for syngeneic antibodies and extracted from epithelial colorectal tumor tissue after extensive lipid extraction. This suggests that a protein-bound carbohydrate determinant, with similarities to the oligosaccharide part of the isoglobo-series glycolipids, is responsible for this cross-reactivity. The staining of rat testis could be explained by the strong expression in this tissue of glycolipids with 8-10 sugar residues bound by the 14.2/10 but not 14.3 MAbs. The cell-surface expression of the 6-sugar hybrid glycolipid was demonstrated by complement-dependent cytotoxicity and immunofluorescent staining of viable cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.